Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC

Lung Cancer

Volumn 62, Issue 1, 2008, Pages 85-91

  Jensen, Lars Henrik ^a   Osterlind, Kell ^b   Rytter, Carsten ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Carboplatin; Combination chemotherapy; NSCLC; Oral chemotherapy; Patient preference; Vinorelbine

Indexed keywords

CARBOPLATIN; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; FEBRILE BONE MARROW APLASIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUESTIONNAIRES; VINBLASTINE;

EID: 52149094045     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.02.009     Document Type: Article

References (23)

1. Chabner B.A., and Roberts Jr. T.G. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5 1 (2005) 65-72
2. Payne S.A. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 35 12 (1992) 1505-1509
3. Marty M., Fumoleau P., Adenis A., Rousseau Y., Merrouche Y., Robinet G., et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12 11 (2001) 1643-1649
4. Jassem J., Ramlau R., Karnicka-Mlodkowska H., Krawczyk K., Krzakowski M., Zatloukal P., et al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Ann Oncol 12 10 (2001) 1375-1381
5. Depierre A., Freyer G., Jassem J., Orfeuvre H., Ramlau R., Lemarie E., et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 12 12 (2001) 1677-1681
6. Gebbia V., and Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 4 5 (2005) 915-928
7. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 2 (2004) 330-353
8. Molina J.R., Adjei A.A., and Jett J.R. Advances in chemotherapy of non-small cell lung cancer. Chest 130 4 (2006) 1211-1219
9. Borner M., Scheithauer W., Twelves C., Maroun J., and Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 6 Suppl. 4 (2001) 12-16
10. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 64 9 Suppl 5 (2007) S4-S7
11. Liu G., Franssen E., Fitch M.I., and Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15 1 (1997) 110-115
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
13. Pfeiffer P., Mortensen J.P., Bjerregaard B., Eckhoff L., Schonnemann K., Sandberg E., et al. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 42 16 (2006) 2738-2743
14. Twelves C., Gollins S., Grieve R., and Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17 2 (2006) 239-245
15. Borner M.M., Schoffski P., de Wit R., Caponigro F., Comella G., Sulkes A., et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38 3 (2002) 349-358
16. Lima A.P., and del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl) 14 2 (2005) 151-154
17. Partridge A.H., Avorn J., Wang P.S., and Winer E.P. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94 9 (2002) 652-661
18. Viele C.S. Managing oral chemotherapy: the healthcare practitioner's role. Am J Health Syst Pharm 64 9 Suppl. 5 (2007) S25-S32
19. Bartel S.B. Safe practices and financial considerations in using oral chemotherapeutic agents. Am J Health Syst Pharm 64 9 Suppl. 5 (2007) S8-S14
20. Hotta K., Matsuo K., Ueoka H., Kiura K., Tabata M., and Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 19 (2004) 3852-3859
21. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99 11 (2007) 847-857
22. Jiang J., Liang X., Zhou X., Huang R., and Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57 3 (2007) 348-358
23. O'Brien M.E., Szczesna A., Karnicka H., Zatloukal P., Eisen T., Hartmann W., et al. Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study. Ann Oncol 15 6 (2004) 921-927